Don't forget they have Cleviprex and cangrelor on deck. Cleviprex--while a good product--isn't going to make them a lot of money, and they're probably going to have a hard time getting it on formularies.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.